IPCA LABORATORIES LTD WALK IN INTERVIEW ON 31st, OCTOBER, 2021 @ INDORE, M.P

ABOUT COMPANY :

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949.

When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti.

This, is how Ipca works.

For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments.

Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others.

Taking the industry forward

• One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally
• 15 APIs & 11 Formulations manufacturing facility across the globe
• Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy in India
• 4 formulations rank amongst the top 300 brands of Indian Pharmaceutical Market as per IQVIA May 2020

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

MULTIPLE DEPARTMENT (ENGINEERING, STORES, EHS) VACANCY IN HETERO DRUGS LTD @ VIZAG

ABOUT COMPANY :

Hetero is a globally renowned vertically integrated pharmaceutical player engaged in research and development, manufacturing, and marketing of high-quality chemical and biologic medicines across diverse therapeutic areas. Backed by 27+ years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, Global Generics, Biosimilars and Custom Pharmaceutical Services. The company is among the largest producers of Active Pharmaceutical Ingredients (APIs) in the world.

Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, which has been approved by top pharma regulatory bodies of the world. Our portfolio includes 300+ products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology etc. Hetero has a strong global presence in over 126 countries and focusses on making affordable medicines accessible to patients worldwide.

Over the years, Hetero has established its strong leadership in ARVs and Antiviral therapies and caters to 40% of existing global demand for Anti-Retroviral (ARV) APIs and Finished Dosage Forms (FDFs) used in HIV/AIDS treatment.

A track record of responding to Global Public Health Emergencies

The highlight of Hetero’s 27+ years of existence has been its responsive actions to mitigate pandemics and life-threatening diseases afflicting communities across the world. By partnering with innovators for developing Oseltamivir to fight against Swine Flu Pandemic to enabling access to affordable Hepatitis C medicines in underdeveloped countries, Hetero has always endeavoured to do its bit at times of global health crises and save precious lives.

Since the onset of the Covid-19 pandemic, Hetero has been proactive in responding to the various challenges surrounding it. It has been the first company to launch the licensed version of generic Remdesivir under the brand name ‘Covifor’ in India for treating severely infected patients and followed it up with Favipiravir (Favivir) to provide succor to those affected by mild and moderate symptoms. As of today, the company is among the largest manufacturers of Remdesivir globally.

Illustrating its continuing commitment to play its part in the global fight against the pandemic, Hetero has entered into an agreement with the Russian Direct Investment Fund (RDIF) as a manufacturing partner for producing 100 million doses of the Sputnik V vaccine per year. This development also showcases Hetero’s enduring spirit of collaboration and penchant for contributing to global health and well-being.

Dear Team, 

Greetings from Hetero Drugs

We are looking for the following positions immediately for API Bulk drug unit located in Nakkapally, Vizag. 

1. Head - EHS 

Experience - 20+yrs with specialisation in Industrial safety. 

2. Head - Mechanical Maintenance

Qualification - B. Tech - Mech ( Regular) 

Experience - 18-25yrs

3. Manager - Electrical Maintenance

Qualification - B. Tech - Electrical ( Regular) 

Experience: 12 -18 yrs

4. Manager - IPQA (API) 

Qualification - M. Sc Chemistry ( Regular) 

Experience - 10 to 15 yrs

5. DGM / AGM - Utility maintenance

Qualification - B. Tech - Mech ( Regular) 

Experience- 20+ yrs

6. Head - Warehouse

Experience - 20+ yrs

7. Manager -  TSD / Technical Services

Qualification - B. Tech - Chemical ( Regular) 

Experience- 10 - 15 yrs

Interested professionals, please share your cv to

srinivasarao.ti@heterodrugs.com

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

OPTIMUS PHARMA LTD WALK IN INTERVIEW FOR PRODUCTION ON 18th, SEPTEMBER, 2021 @ VIZAG

ABOUT COMPANY :

Optimus was established in the year 2004 as custom synthesis laboratory by a team of Technocrats. It is one of the fastest growing Manufacturer in Active Pharmaceutical Ingredients (APIs) and Finished dosages.

We expanded into global markets and started filing DMFs for both APIs and Intermediates with various Regulatory agencies.

Optimus Research Center for API & Formulations was set-up as a centralized Research and Development center to focus on Generic product developments suitable for regulated markets.

Optimus Pharma is an integrated pharmaceutical organization engaged in manufacturing of Solid Oral and semisolid formulations.

We have dedicated API manufacturing plants and R&D Centres with a team of Scientists who had a passion towards chemistry and to ensure a better healthcare to everyone.

We help our customers serve global markets with technology based, innovative, cost effective & consumer friendly products of the highest quality.

In the journey of more than a decade Optimus developed many molecules and have emerged as one of the reputed manufacturing company in the industry.

The Optimus group today employs directly about 950 people and provides indirect employment to about 600 across the group. The group has well qualified professionals from all fields and heading the various functional verticals of the Optimus Corporate Group.

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

AUROBINDO PHARMA LTD HIRING CANDIDATES FOR TTD (TECHNOLOGY TRANSFER@ NAIDUPETA , NELLORE

                                         

ABOUT COMPANY :

Founded in 1986 by Mr. P. V. Ramprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born of a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry.

Aurobindo Pharma became a public company in 1992 and listed its shares on the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and anti-biotics, among others.

VACANCY DETAILS :

Send Resumes Who are willing to relocate Nayudupeta Only 

Send RESUMES On and before 04/08/2021

COMPANY : Aurobindo Pharma Ltd

JOB LOCATION : Nayudupeta , Nellore (Dt), Andra Pradesh

DEVISON : Formulation

DEPARTMENTS: TTD (TECHNOLOGY TRANSFER) 

Designation :  Executive

QUALIFICATION : B.Pharm/ M.Pharm

             

EXPERIENCE : Should have minimum experience of 2-7 years.

In subject Mention your " AUROBINDO"

Interest candidates send resume to globalpharmanews@gmail.com

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

TORRENT PHARMA WALK IN INTERVIEW ON 08th, AUGUST, 2021 @ VAPI, GUJARAT

ABOUT COMPANY :

Torrent Pharma, the flagship Company of Torrent Group is one of the leading pharma companies of the Country. The Company was a pioneer in initiating the concept of niche marketing in India and and today is ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments.

Torrent Pharma's competitive advantage stems from the world-class manufacturing facilities, advanced R & D capabilities, extensive domestic network and a widespread global presence in over 40 countries.

The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceutical business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market.

Torrent Pharma started international acquisitions in 2005 with 90 year old Heumann from Pfizer to enter the German market. Later on purchased ANDA of Minocycline from Ranbaxy for the US Market in 2015.

In January 2018, Torrent also acquired Bio-Pharm, Inc. (BPI) a generic pharmaceuticals and OTC Company, based in Levittown Pennsylvania, USA, which also included a US FDA registered manufacturing facility.

Torrent Pharma is committed towards “not just healthcare but lifecare.”

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

SUN PHARMACEUTICAL INDUSTRIES LTD WALK IN INTERVIEW ON 4th, AUGUST, 2021 @ DAHEJ, BHARUCH, GUJARAT

ABOUT COMPANY :

Sun Pharmaceutical Industries Ltd. (Sun Pharma) is the fourth largest specialty generic pharmaceutical company in the world with global revenues of over US$ 4.5 billion. Supported by more than 40 manufacturing facilities, we provide high-quality, affordable medicines, trusted by healthcare professionals and patients, to more than 100 countries across the globe.

We manufacture and market a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult to make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and Intermediates. Our broad portfolio of more than 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids.

Every year, we sell over 30 billion doses covering neuro-psychiatry, cardiology, gastroenterology, anti-infectives, diabetology, oncology, ophthalmology, dermatology, urology, nephrology and respiratory among others.

The first among Indian pharmaceutical companies to realise and embrace the importance of investing in research, we invest up to 7-8% of our global revenues into Research and Development (R&D) every year.

Our core strength lies in our ability to excel in developing generics and technologically complex products backed by our dedicated teams in formulations, process chemistry, and analytical development.

Our capabilities extend beyond the development of differentiated products, including liposomal products, inhalers, lyophilized injections, nasal sprays, and controlled release dosage forms.

Our R&D is led by a strong team of more than 2000 scientists.

From humble beginnings in 1983, Sun Pharma has grown to become one of the largest generic pharmaceutical companies worldwide. We are the largest pharmaceutical company in India.

In the US, we are among the top 10 generic pharmaceutical companies and are ranked second by prescriptions in the generic dermatology market.

We are the largest Indian company in emerging markets with a presence in over 80 markets. Brazil, Mexico, Russia, Romania and South Africa are some of our key emerging markets.

We are present across all major markets in Western Europe, Canada, Australia, New Zealand, Japan and China among others.

Our presence in emerging markets and the developing world enables our teams to cross-sell and build brands with ease.

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

SAI LIFE SCIENCES WALK IN INTERVIEW ON 7th, AUGUST, 2021 @ HYDERABAD

ABOUT COMPANY :

Sai Life Sciences is one of India’s fastest growing Contract Research, Development & Manufacturing Organizations. As a pure-play, full-service CRO-CDMO, we work with over a 100 global innovator pharma and biotech companies to accelerate the discovery, development, and commercialisation of their NCE small molecule programmes.

Over the past two decades, Sai Life Sciences has served a diverse set of programmes, consistently delivering value based on its quality and responsiveness. Today, it has over 2000 employees across its facilities in India, UK and USA.

At Sai Life Sciences, we deliver scientific expertise with a greater purpose – to impact tomorrow’s healthcare by creating medicines for today’s incurable maladies. We work with innovator pharma and biotech companies to accelerate the discovery, development and manufacture of complex small molecules for a healthier tomorrow. Our Vision is to support our global innovator partners bring 25 new medicines to life by 2025. And we are well on that journey.

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

AMNEAL PHARMACEUTICALS PVT LTD WALK IN INTERVIEW ON 07th AUGUST, 2021 @ AHMEDABAD

                                 

                                 

ABOUT COMPANY :

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) is an integrated specialty pharmaceutical company powered by a robust U.S. generics business and a growing branded business. Together, our team is working to build one of the most dynamic pharmaceutical companies in our rapidly changing industry.

Today’s healthcare environment requires a new approach and new ideas. While staying true to our reputation for quality, service and value, we are reinventing our processes, our playbook and our creative partnerships. We are focused on delivering outcomes that meet important medical needs, make quality medicines more accessible and more affordable, and provide solutions for tomorrow’s health challenges.

Our leadership and global colleagues are deeply experienced and forward-thinking. We have the capabilities, scale and resources for growth and success. We are nimble and determined. We are Amneal and We make healthy possible.

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

PFIZER WALK IN INTERVIEW FOR VIZAG PLANT ON 8th, AUGUST, 2021 @ AHMEDABAD

                        

ABOUT COMPANY :

The pursuit of delivering breakthroughs is basic to Pfizer's culture. It shapes our strategy, defines our purpose, and governs every facet of our operations -- from research and development (R&D) that leads to pharmaceutical inventions, to the transfer of knowledge to patients and providers, to the way we respond to the changing marketplace.

Pfizer scientists have produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections. And today we're taking on some of the world's most difficult diseases, including cancer, arthritis, and osteoporosis.

Pfizer Limited was listed on the Indian stock exchange in 1966. Today, the company has over one lac shareholders in India. With annual sales of over Rs. 2,000 crores, it is the fourth largest multinational pharmaceutical company in India. The Company has a portfolio of over 150 products across 15 therapeutic areas.

Its top brands include Prevenar 13, Lyrica, Corex – DX, Dolonex, Enbrel, Becosules, Gelusil and Folvite among others. In addition to its commercial operations, Pfizer Limited also operates a state-of-the-art, award-winning manufacturing facility in Goa that produces more than a billion tablets annually.

The Company employs 2,631 colleagues, and is committed to providing therapies to prevent and treat some of the most critical diseases that impact public health in India today.

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

INTAS PHARMACEUTICALS LTD WALK IN INTERVIEW ON 08th, AUGUST, 2021 @ AHMEDABAD

 

ABOUT COMPANY :

Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas is committed to challenging the unmet medical and societal needs through a comprehensive pharmaceutical value chain spanning across the world.

Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central & Latin America, Asia-Pacific as well as CIS and MENA countries. Intas’ remarkable success in North America and European operations have helped us emerge as a global brand in the world’s largest pharmaceutical markets.

Every Intas product and service is a testament to its uncompromising quality standards. All products are manufactured in facilities that are approved by major global regulatory agencies including the USFDA, MHRA, EMA, TGA, MCC, ANVISA and more. Today, a segment-leading pipeline and strong in-house development capabilities allow Intas to compete with some of the biggest portfolios in the industry. Intas is currently investing in a higher barrier to entry developments such as Biosimilar and New Chemical Entities and is set to continue raising the bar of healthcare excellence, globally in the near future.

Intas believes in empowering people. Therefore, to fulfil its corporate vision, Intas aims to acquire and retain the best talent across the industry to fully leverage the diversity of respective markets they operate in.

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

RAKS PHARMA PVT LTD (DIVISON OF AMNEAL PHARMACEUTICALS) HIRING CANDIDATES FOR QC DEPARTMENT @ VIZAG

 

ABOUT COMPANY :

We at Raks are dedicated to develop and manufacture active pharmaceutical ingredients and intermediates. We are committed to create value through intellectual property, quality systems and customer relation across the globe. We are research driven company providing cost effective and environmental friendly technologies with safety and quality as primary focus.

M/s. RAKS Pharma was conceptualized to become a significant API player so as to manufacture & supply APIs & Drugs Intermediate to Regulated & Non-Regulated Market from its present manufacturing site in Visakhapatnam (Andhra Pradesh), and upcoming unit in Dahej (Gujarat) India.

Raks is an interesting blend of consistency in maintaining both quality standard and growth in terms of addition of new products to its existing list of API's and intermediates. To realize this goal it has a team of experienced, dedicated and highly motivated professionals in all fields of the business.

Founded by a group of highly committed Technocrats in year 2009, today Raks Pharma is a partner of choice for pharmaceutical companies across the globe to source Active Pharmaceuticals Ingredients and their intermediates.

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

NEUHEIT PHARMA TECHNOLOGIES PVT LTD WALK IN INTERVIEW ON 08th, AUGUST, 2021 @ HYDERABAD

ABOUT COMPANY :

Neuheit Pharma Technologies Private Ltd is a Hyderabad based Research & Development Company specializing in the research and development of pharmaceutical drug products (for marketing authorizations in global regulated markets). The company is pro-actively involved in development of complex generic and differentiated products from ideation to commercialization. It also offers consultancy services in all disciplines of pharmaceutical product development including pharmacokinetic design and modeling with emphasis on bioequivalence and bioavailability studies. Our key strength is developing novel approaches for bio/clinical waiver strategies and 505(b) (2) product ideational development.  We intend to grow in the ever expanding global pharmaceutical industry by collaborating with strategic partners in different disciplines of formulations.

Neuheit Pharma Technologies Private Ltd established in 2013, is a Research & Development company that provides Creative Solutions for Human Suffering by developing complex generics and innovative products that offer clinical advantage to the patient. The company is started with solid orals and expanded to liquid orals & Injectables (general and high potent).  Currently expansion is in progress towards the development of dermal/topical R & D facility. Separate manufacturing facility for solid orals for regulatory market is also in progress.

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

FIDELITY HEALTH SERVICES HIRING CANDIDATES FOR PHARMACOVIGILANCE DEPARTMENT @ MUMBAI

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

ALKEM LABORATORIES LTD WALK IN INTERVIEW ON 7th, AUGUST, 2021 @ DAMAN

ABOUT COMPANY :

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did!

Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries

33% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged.

We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries.

Another feather in our cap was added on December 23rd, 2015, when, Alkem completed its Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited.

Although, passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 6 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

ACCORD LIFE SPEC PVT LTD WALK IN INTERVIEW ON 10th, AUGUST, 2021 @ CHENNAI

ABOUT COMPANY :

Headquartered in Chennai, India, Accord Labs is a fast-growing generic pharmaceutical company with a major focus on development and manufacture of IP led niche finished dosage formulations and Active pharmaceutical ingredients (APIs).

Accord is involved in Research & Development, Manufacturing and Supply of pharmaceuticals across different geographical entities around the globe.

We are always building on our company's core strengths of vertical integration in the fields of discovery, research, process chemistry, active pharmaceutical ingredient production, formulation development and regulatory filings. Accord Pharmaceuticals, is committed to achieving its vision and mission of invariably becoming the most innovation led transnational pharmaceutical company.

Inseminating quintessential aspects into our system to satisfy a wide array of criteria, the accord group always strives to be more and thereby aspire to be the best.Our partnership philosophy with our customers has helped deliver incremental value to both our company and partners.

Fulfilling the demands of the world markets - Accord Pharma aim at building on our strong global footprint, we are committed to fulfilling the demands of the world markets by anticipating the future needs and pioneering strategic new in-roads into the commercial pharmaceutical sector.

Also, we focus on building an enterprise that generates value for all its stakeholders.We are focused on fulfilling the demands of the world markets through different business segments.

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE